226 related articles for article (PubMed ID: 34529358)
1. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
2. A robust platform for expansion and genome editing of primary human natural killer cells.
Huang RS; Lai MC; Shih HA; Lin S
J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33433623
[TBL] [Abstract][Full Text] [Related]
3. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
4. Efficient Cas9-based Genome Editing Using CRISPR Analysis Webtools in Severe Early-onset-obesity Patient-derived iPSCs.
Patel A; Iannello G; Diaz AG; Sirabella D; Thaker V; Corneo B
Curr Protoc; 2022 Aug; 2(8):e519. PubMed ID: 35950852
[TBL] [Abstract][Full Text] [Related]
5. Efficient and stable CRISPR/Cas9-mediated genome-editing of human type 2 innate lymphoid cells.
Audouze-Chaud J; Mathews JA; Crome SQ
Front Immunol; 2023; 14():1275413. PubMed ID: 37868976
[TBL] [Abstract][Full Text] [Related]
6. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
[TBL] [Abstract][Full Text] [Related]
7. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
Front Immunol; 2020; 11():1008. PubMed ID: 32528479
[TBL] [Abstract][Full Text] [Related]
8.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
Methods Mol Biol; 2020; 2121():213-239. PubMed ID: 32147798
[TBL] [Abstract][Full Text] [Related]
10. Efficient Multi-Allelic Genome Editing of Primary Cell Cultures via CRISPR-Cas9 Ribonucleoprotein Nucleofection.
Hoellerbauer P; Kufeld M; Paddison PJ
Curr Protoc Stem Cell Biol; 2020 Sep; 54(1):e126. PubMed ID: 32833346
[TBL] [Abstract][Full Text] [Related]
11. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.
Naeimi Kararoudi M; Dolatshad H; Trikha P; Hussain SA; Elmas E; Foltz JA; Moseman JE; Thakkar A; Nakkula RJ; Lamb M; Chakravarti N; McLaughlin KJ; Lee DA
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985369
[TBL] [Abstract][Full Text] [Related]
12. Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samples.
Eerkens AL; Vledder A; van Rooij N; Foijer F; Nijman HW; de Bruyn M
Immunol Cell Biol; 2022 Apr; 100(4):285-295. PubMed ID: 35194830
[TBL] [Abstract][Full Text] [Related]
13. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
Bexte T; Alzubi J; Reindl LM; Wendel P; Schubert R; Salzmann-Manrique E; von Metzler I; Cathomen T; Ullrich E
Oncoimmunology; 2022; 11(1):2081415. PubMed ID: 35694192
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas9 Genome Editing and Rapid Selection of Cell Pools.
Stoyko D; O T; Hernandez A; Konstantinidou P; Meng Q; Haase AD
Curr Protoc; 2022 Dec; 2(12):e624. PubMed ID: 36546759
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9 Genome Editing of Primary Human Vascular Cells In Vitro.
Atri DS; Lee-Kim VS; Vellarikkal SK; Sias-Garcia O; Yanamandala M; Schniztler GR; Gupta RM
Curr Protoc; 2021 Nov; 1(11):e291. PubMed ID: 34748284
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 Genome Editing in the Moss Physcomitrium (Formerly Physcomitrella) patens.
Wu SZ; Ryken SE; Bezanilla M
Curr Protoc; 2023 Apr; 3(4):e725. PubMed ID: 37021953
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
[TBL] [Abstract][Full Text] [Related]
20. Simple Protocol for Generating and Genotyping Genome-Edited Mice With CRISPR-Cas9 Reagents.
Fernández A; Morín M; Muñoz-Santos D; Josa S; Montero A; Rubio-Fernández M; Cantero M; Fernández J; Del Hierro MJ; Castrillo M; Moreno-Pelayo MÁ; Montoliu L
Curr Protoc Mouse Biol; 2020 Mar; 10(1):e69. PubMed ID: 32159922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
